European retrospective study of real‐life haemophilia treatment
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Introduction: Haemophilia treatment varies significantly between individuals, countries and regions and details of bleed rates, factor consumption and injection frequency are often not available. Aim: To provide an overview of the FVIII/FIX treatment practice and outcome for patients with haemophilia A (HA) or haemophilia B (HB) across Europe. Methods: Non‐interventional, 12‐month retrospective study where anonymized data were retrieved from haemophilia centres/registers in Belgium, France, Germany, Italy, Spain, Sweden and the United Kingdom. Male patients (all ages) receiving coagulation factor treatment 24 months prior to the study, with basal FVIII/FIX levels ≤5 IU dL−1, without inhibitors, were included. Data were summarized descriptively. Results: In total, 1346 patients with HA and 312 with HB were included in the analysis; 75% and 57% had severe disease (FVIII/FIX < 1 IU dL−1) respectively. Prophylaxis was most common for severe haemophilia, especially for children, whereas on‐demand treatment was more common for moderate haemophilia in most countries. The mean (SD) prescribed prophylactic treatment ranged from 67.9 (30.4) to 108.4 (78.1) (HA) and 32.3 (10.2) to 97.7 (32.1) (HB) IU kg−1 per week, across countries. Most patients on prophylaxis were treated ≥3 times/week (HA) or two times/week (HB). The median annual bleeding rate (ABR) for patients on prophylaxis ranged from 1.0 to 4.0 for severe HA, and from 1.0 to 6.0 for severe HB, while those with moderate haemophilia generally had slightly higher ABR s. Median ABR s for on‐demand‐treated severe HA ranged from 4.5 to 18.0, and for HB, 1.5 to 14.0. Conclusion: Treatment practice varied greatly between centres and countries and patients treated on‐demand and prophylactically both experienced bleeds, emphasizing the need for further optimization of care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950
Men with severe hemophilia in the United States: birth cohort analysis of a large national database
Mazepa, M. A., Monahan, P. E., Baker, J. R., Riske, B. K., & Soucie, J. M. (2016) · Blood · doi:10.1182/blood-2015-10-675140 · Cited by 117
Cited by
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694
Klamroth, R., Hayes, G., Andreeva, T., Gregg, K., Suzuki, T., Mitha, I. H., Hardesty, B., Shima, M., Pollock, T., Slev, P., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.287 · Cited by 118
Self-citationPharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review
Donners, A. A. M. T., Rademaker, C. M. A., Bevers, L. A. H., Huitema, A. D. R., Schutgens, R. E. G., Egberts, T. C. G., & Fischer, K. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01042-w · Cited by 40
Metadata
- Authors
- Berntorp, E., Dolan, G., Hay, C., Linari, S., Santagostino, E., Tosetto, A., Castaman, G., Álvarez‐Román, M., Parra Lopez, R., Oldenburg, J., Albert, T., Scholz, U., Holmström, M., Schved, J. ‐., Trossaërt, M., Hermans, C., Boban, A., Ludlam, C., & Lethagen, S.
- Venue
- Haemophilia
- Publisher
- Wiley
- Published
- 2016-10-20
- Volume
- 23
- Issue
- 1
- Pages
- 105-114
- ISSN
- 1351-8216 (ISSN-L)
- 1365-2516
- OpenAlex
- W2535041295
- Cited by
- 77
- References
- 2
- FWCI
- 7.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: European retrospective study of real‐life haemophilia treatment. https://app.cochat.ai/papers/10.1111/hae.13111
- The paper
- Berntorp, E., Dolan, G., Hay, C., Linari, S., Santagostino, E., Tosetto, A., Castaman, G., Álvarez‐Román, M., Parra Lopez, R., Oldenburg, J., Albert, T., Scholz, U., Holmström, M., Schved, J. ‐., Trossaërt, M., Hermans, C., Boban, A., Ludlam, C., & Lethagen, S. (2017). European retrospective study of real‐life haemophilia treatment. Haemophilia. https://doi.org/10.1111/hae.13111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.